| Similar Articles |
|---|
 |
The Motley Fool
December 31, 2007
Brian Lawler |
Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.   |
The Motley Fool
December 21, 2004
Brian Gorman |
Bristol-Myers, Gilead Team Up The drugmakers' alliance will benefit both the companies and HIV patients. |
The Motley Fool
October 20, 2010
Brian Orelli |
What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back. |
The Motley Fool
July 30, 2004
Roger Nusbaum |
Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability. |
The Motley Fool
July 17, 2009
Brian Orelli |
Have a Cocktail Two virus killers are better than one. The latest two to hook up are Gilead Sciences and Johnson & Johnson. |
AskMen.com
Dave Golokhov |
Truvada With more and more studies finding successful AIDS prevention, it looks like we're getting closer to finding a cure. |
The Motley Fool
July 27, 2011
Brian Orelli |
Not Hypergrowth, but Good Enough Gilead posts a double-digit revenue gain. |
BusinessWeek
April 25, 2005
Sarah Lacy |
BW50: Gilead's Big Growth Spurt The small biotech rivals the majors in HIV drugs. Now it must expand beyond its niche |
The Motley Fool
July 21, 2006
Brian Lawler |
Gilead's Acquisitive Mood Trading at around 28 times 2006 EPS estimates, and with 40% growth expected for its HIV franchise, Gilead offers tempting value -- assuming it makes smart use of that cash sitting on the balance sheet. |
The Motley Fool
January 6, 2010
Brian Orelli |
Gilead Goes It Alone ... for Now Investors jump for joy as Gilead Sciences announces what on the surface sounds like rather inconsequential data. |
The Motley Fool
April 24, 2007
Brian Lawler |
Gilead's Sales Are Galloping Ahead The biotech giant announces first-quarter financial results, with its most important drugs showing no weakness. What's important for investors to figure out is whether the valuation on shares of Gilead needs to shrink or expand in order to meet its future financial fortunes. |
The Motley Fool
January 27, 2011
Brian Orelli |
Gilead's Once in a Decade Quarter Gilead's revenue falls for the first time in more than a decade. |
The Motley Fool
August 9, 2011
Brian Orelli |
Some Potential Good News in Biotech The FDA should approve Gilead's Btripla. |
The Motley Fool
January 27, 2010
Brian Orelli |
The Virus-Killer's Killer Quarter Gilead Sciences closed out 2009 with a solid 42% increase in revenue in the fourth quarter, thanks to its HIV drugs. |
The Motley Fool
May 24, 2011
Brian Orelli |
J&J Approved, but Needs Help From a Friend The HIV combo product is the key. |
The Motley Fool
May 19, 2004
Roger Nusbaum |
Gilead Shines This biotech company looks strong because investors can relate to its products. |
The Motley Fool
June 12, 2008
Brian Lawler |
Gilead's Got the Goods As long as Gilead Sciences makes good use of its cash, its long-run future looks bright. |
The Motley Fool
July 23, 2007
Brian Lawler |
Gilead's Great Growth The drugmaker announces another great quarter of growth. Investors, take note. |
The Motley Fool
February 27, 2007
Brian Lawler |
Gilead's Green-Lighted Drug Having a diversified drug pipeline is what makes large-cap drug stocks like Gilead so enticing, even to risk-adverse investors. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
April 22, 2009
Brian Orelli |
Better Than Recession-Proof The whole health-care industry may not be recession-proof, but Gilead has shown that the right combination of drugs can lead to stellar returns -- even in a down economy. |
The Motley Fool
February 18, 2010
Brian Orelli |
Gilead Shareholders Are Whistling a Happy Tune Full data from the company's HIV quad pill show no major issues. |
BusinessWeek
April 1, 2010
Bennett & Randall |
Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists. |
The Motley Fool
October 19, 2006
Brian Lawler |
No Gilded Quarter for Gilead The company's recent acquisition may help it become a diversified drug giant. Investors, take note. |
The Motley Fool
March 20, 2008
Brian Lawler |
Gilead Not Slowing Gilead Sciences gets a new approval for a drug. |
The Motley Fool
October 7, 2011
Brian Orelli |
A Little Help, Please Gilead pumps up the pipeline. |
The Motley Fool
July 21, 2010
Brian Orelli |
15% Revenue Growth Is Good for Pfizer, but Not Gilead Gilead needs to reaccelerate growth. |
The Motley Fool
October 21, 2009
Brian Orelli |
Double-Digit Growth in a Recession The strong double-digit growth at Gilead shouldn't be much of a surprise; HIV patients need their medication even in a recession. |
The Motley Fool
February 5, 2007
Brian Lawler |
Gilead's Gold Mine In the fourth quarter, the pharmaceutical continues to rake in the cash from its top products. Investors, take note. |
The Motley Fool
January 28, 2009
Brian Orelli |
Worth Every Penny People still need to take their antiviral medication even if the purse strings are tight, and that fact has led Gilead Sciences to putting together another great quarter. |
The Motley Fool
February 23, 2011
Brian Orelli |
Gilead Gears Up to Fight Cancer Gilead has been infected by the diversification bug. |
Fast Company
March 2015
J.J. McCorvey |
How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone. |
The Motley Fool
September 20, 2011
Brian Orelli |
Phase 3 + Phase 3 = Quad Approval Will Gilead Sciences' new four-drug HIV cocktail sell? |
The Motley Fool
February 23, 2010
Brian Orelli |
The One That Didn't Get Away After some encouragement, the FDA approves Gilead's Cayston. |
BusinessWeek
February 19, 2007
Arlene Weintraub |
How Gilead Primed The Pipeline Gilead's $2.5 billion purchase of Myogen offers instant diversification from its HIV drug focus. |
Pharmaceutical Executive
September 1, 2010 |
Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? |
The Motley Fool
June 25, 2010
Brian Orelli |
Diversification Times 50,000 Gilead Sciences diversifies any way it can. |
The Motley Fool
July 12, 2011
Tracy Staton |
Gilead First to Jump Into AIDS Patent Pool Gilead Sciences has broken the ice on the AIDS drug patent pool. |
The Motley Fool
March 31, 2011
Brian Orelli |
Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious. |
The Motley Fool
October 17, 2008
Brian Orelli |
Gilead Sciences Killed It The virus-killer kills analysts' expectations, as well. The company blows through analysts' expectations with its third-quarter results. |
The Motley Fool
July 19, 2010
Brian Orelli |
Abbott Labs Loves Merck More Than Gilead Its HIV trial seems to suggest so. |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
BusinessWeek
September 18, 2006
Gene G. Marcial |
Gilead Has "Room To Run" Most pharmaceutical companies are limping, but Gilead Sciences has sprinted. |
The Motley Fool
March 24, 2011
Brian Orelli |
It's the Combo That Matters for Gilead The same efficacy with fewer pills is the headline, but it's the understory that makes Gilead Sciences' latest clinical trial success important for investors. |
The Motley Fool
November 27, 2009
Brian Orelli |
A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence. |
The Motley Fool
January 25, 2008
Brian Lawler |
What's Not to Like About Gilead? Gilead is looking more and more like a diversified pharma with a robust clinical-stage pipeline and growing cash flows. |
BusinessWeek
March 26, 2009
Aili McConnon |
Gilead Sciences: High-Performing Pharmaceutical Gilead owes much of its success to making it easier for patients to comply with complex and uncomfortable drug regimens. |
The Motley Fool
December 16, 2009
Brian Orelli |
Gilead's Phase 3 Train Wreck Gilead Sciences' darusentan looked so promising. |
The Motley Fool
July 22, 2009
Brian Orelli |
Grab Hold of This Growth Double-digit growth just keeps coming for Gilead Sciences. |
The Motley Fool
March 29, 2010
Brian Orelli |
5 Drugmakers Producing Cash for You Take greenbacks over earnings any day. |
